The Oncologist
Volume 9, Supplement 3, 2004

The Future of ErbB1 and ErbB2 Pathway Inhibition in Breast Cancer: Targeting Multiple Receptors

Supported by an unrestricted educational grant from GlaxoSmithKline.

Click here to go to the supplement Table of Contents